• ISSN 1674-8301
  • CN 32-1810/R
Volume 27 Issue 4
Jul.  2013
Turn off MathJax
Article Contents

Zhengshan Wu, Qingyang Meng, Yongxiang Xia, Feng Zhang, Wei You. A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients[J]. The Journal of Biomedical Research, 2013, 27(4): 305-309. doi: 10.7555/JBR.27.20130023
Citation: Zhengshan Wu, Qingyang Meng, Yongxiang Xia, Feng Zhang, Wei You. A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients[J]. The Journal of Biomedical Research, 2013, 27(4): 305-309. doi: 10.7555/JBR.27.20130023

A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients

doi: 10.7555/JBR.27.20130023
  • Received Date: 2013-01-14
  • Publish Date: 2013-07-28
  • We sought to evaluate the efficacy and effects of low-dose tacrolimus (FK506) to recipients with living donor liver transplantation (LDLT). A total of 66 patients who underwent LDLT between 2001 and 2007 were enrolled in this study. According to different doses of tacrolimus, the recipients were randomly divided into two groups: the low-dose tacrolimus group (group A) and the normal-dose tacrolimus group (group B). The blood concentra-tion of tacrolimus and its side effects including infection, hyperglycemia, hypertension, high blood creatinine and jaundice were monitored once a week at the perioperative period, and once a month thereafter. Besides, the sur-vival rates of the recipients were analyzed at the 1- and 3-year time point after operation. Among these patients, no significant acute rejection was detected after LDLT. The incidences of infection, hyperglycemia, liver dys-function and renal impairment in group A were markedly lower than those in group B. However, no significant differences were detected in the incidence of hypertension between the two groups. Moreover, the recipients in each group had a similar survival rate according to the results of 1- and 3-year follow-up. The incidence of side effects that associated with tacrolimus positively correlated with tacrolimus blood concentration. In conclusion, long-term and low-dose administration of tacrolimus is a safe and effective treatment for LDLT recipients.
  • 加载中
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(2871) PDF downloads(817) Cited by()

Related
Proportional views

A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients

doi: 10.7555/JBR.27.20130023

Abstract: We sought to evaluate the efficacy and effects of low-dose tacrolimus (FK506) to recipients with living donor liver transplantation (LDLT). A total of 66 patients who underwent LDLT between 2001 and 2007 were enrolled in this study. According to different doses of tacrolimus, the recipients were randomly divided into two groups: the low-dose tacrolimus group (group A) and the normal-dose tacrolimus group (group B). The blood concentra-tion of tacrolimus and its side effects including infection, hyperglycemia, hypertension, high blood creatinine and jaundice were monitored once a week at the perioperative period, and once a month thereafter. Besides, the sur-vival rates of the recipients were analyzed at the 1- and 3-year time point after operation. Among these patients, no significant acute rejection was detected after LDLT. The incidences of infection, hyperglycemia, liver dys-function and renal impairment in group A were markedly lower than those in group B. However, no significant differences were detected in the incidence of hypertension between the two groups. Moreover, the recipients in each group had a similar survival rate according to the results of 1- and 3-year follow-up. The incidence of side effects that associated with tacrolimus positively correlated with tacrolimus blood concentration. In conclusion, long-term and low-dose administration of tacrolimus is a safe and effective treatment for LDLT recipients.

Zhengshan Wu, Qingyang Meng, Yongxiang Xia, Feng Zhang, Wei You. A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients[J]. The Journal of Biomedical Research, 2013, 27(4): 305-309. doi: 10.7555/JBR.27.20130023
Citation: Zhengshan Wu, Qingyang Meng, Yongxiang Xia, Feng Zhang, Wei You. A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients[J]. The Journal of Biomedical Research, 2013, 27(4): 305-309. doi: 10.7555/JBR.27.20130023

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return